USFDA ir apstiprinājusi pembrolizumabu ar ķīmijradioterapiju FIGO 2014 III-IVA dzemdes kakla vēža ārstēšanai.
The Food and Drug Administration authorized pembrolizumab (Keytruda, Merck) in combination with chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer on January 12, 2024.A study called KEYNOTE-A18 (NCT..
Enfortumab vedotin-ejfv ar pembrolizumabu ir apstiprinājusi USFDA lokāli progresējoša vai metastātiska urotēlija vēža ārstēšanai
As of December 15, 2023, the Food and Drug Administration (FDA) approved enfortumab vedotin-ejfv (Padcev, Astellas Pharma) along with pembrolizumab (Keytruda, Merck) for people who have locally advanced or metastatic urothelial c..
USFDA ir apstiprinājusi Belzutifānu progresējošas nieru šūnu karcinomas ārstēšanai
The Food and Drug Administration granted approval for belzutifan (Welireg, Merck & Co., Inc.) on December 14, 2023, for patients with advanced renal cell carcinoma (RCC) who have previously received a programmed death recepto..
Pirtobrutinibu ir apstiprinājusi USFDA hroniskas limfoleikozes un mazās limfocītiskās limfomas ārstēšanai
The Food and Drug Administration granted accelerated approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) on December 1, 2023, for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have u..
Nirogacetātu ir apstiprinājusi USFDA desmoīdiem audzējiem
The Food and Drug Administration authorized nirogacestat (OGSIVEO, SpringWorks Therapeutics, Inc.) on November 27, 2023, for adult patients with advancing desmoid tumors needing systemic treatment. This is the initial authorized ..
Fruquintinibu ir apstiprinājusi USFDA ugunsizturīga metastātiska kolorektālā vēža gadījumā
The Food and Drug Administration approved fruquintinib (Fruzaqla, Takeda Pharmaceuticals, Inc.) on November 8, 2023, for adult patients with metastatic colorectal cancer (mCRC) who have undergone specific prior treatments.Efficac..
Enzalutamīdu ir apstiprinājusi USFDA nemetastātiska kastrācijas jutīga prostatas vēža ārstēšanai ar bioķīmisku recidīvu
The FDA has authorized enzalutamide for the treatment of non-metastatic castration-sensitive prostate cancer in cases of biochemical recurrence.The Food and Drug Administration approved enzalutamide (Xtandi, Astellas Pharma US, I..
Kapivasertibu ar fulvestrantu ir apstiprinājusi USFDA krūts vēža ārstēšanai
Capivasertib (Truqap, AstraZeneca Pharmaceuticals) in combination with fulvestrant was approved by the Food and Drug Administration on November 16, 2023, for adult patients with hormone receptor (HR)-positive, human epidermal gro..
USFDA ir apstiprinājusi pembrolizumabu ar ķīmijterapiju HER2 negatīvai kuņģa vai gastroezofageālā savienojuma adenokarcinomas ārstēšanai
The Food and Drug Administration approved pembrolizumab (Keytruda, Merck) in combination with fluoropyrimidine- and platinum-containing chemotherapy on November 16, 2023. This approval is for the initial treatment of adults with ..
USFDA ir apstiprinājusi repotrektinibu ROS1 pozitīva nesīkšūnu plaušu vēža ārstēšanai
The Food and Drug Administration authorized repotrectinib (Augtyro, Bristol-Myers Squibb Company) for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) on November 15, 2023.This FDA approval is the f..